NCT04652960 2026-03-18
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
6 trialsNCT05044039 2026-02-02
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05065866 2025-12-04
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05010005 2025-12-03
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07001384 2025-08-14
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT02783625 2025-06-03
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting